Interleukin-6 signaling blockade treatment for cytokine release syndrome in COVID-19 (Review)

Eitemau Tebyg

• Interleukin-6 and other cytokine blockade in COVID-19 hyperinflammation
  gan: Latika Gupta, et al.
  Cyhoeddwyd: (2020-01-01)
• Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?
  gan: Liu, Bingwen, et al.
  Cyhoeddwyd: (2020)
• Interleukin‐6 blockade treatment for COVID‐19 associated cytokine release syndrome in a patient with poorly controlled chronic myeloid leukaemia
  gan: Ranger, Amita, et al.
  Cyhoeddwyd: (2020)
• Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality
  gan: Zhang, Chi, et al.
  Cyhoeddwyd: (2020)
• The conundrum of interleukin-6 blockade in COVID-19
  gan: Campochiaro, Corrado, et al.
  Cyhoeddwyd: (2020)